2017
DOI: 10.1002/lt.24782
|View full text |Cite
|
Sign up to set email alerts
|

The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation

Abstract: The purpose of this study was to evaluate the feasibility of living donor liver transplantation for treatment of patients with hepatocellular carcinoma and segmental portal vein tumor thrombus (PVTT) below the second-order branch. Between January 2005 and December 2015, we retrospectively analyzed 242 patients in a control group (n = 184), a microvascular invasion (MVI) group (n = 24), and a PVTT group (n = 34). To assess the risks associated with PVTT, we evaluated recurrence, the disease-free survival (DFS) … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
51
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(52 citation statements)
references
References 20 publications
1
51
0
Order By: Relevance
“…The immunosuppression regimen consisted of 3 drugs, including a calcineurin inhibitor (tacrolimus or cyclosporine), mycophenolate mofetil (MMF), and steroid (prednisolone), in accordance with our hospital’s LDLT protocol [ 9 ]. The trough level of tacrolimus was maintained within 7 and 10 ng/mL for the first month after LDLT, and within 5 and 7 ng/mL thereafter.…”
Section: Methodsmentioning
confidence: 99%
“…The immunosuppression regimen consisted of 3 drugs, including a calcineurin inhibitor (tacrolimus or cyclosporine), mycophenolate mofetil (MMF), and steroid (prednisolone), in accordance with our hospital’s LDLT protocol [ 9 ]. The trough level of tacrolimus was maintained within 7 and 10 ng/mL for the first month after LDLT, and within 5 and 7 ng/mL thereafter.…”
Section: Methodsmentioning
confidence: 99%
“…[ 15 ] All of the patients who underwent LDLT were given immunosuppression such as tacrolimus, mycophenolate mofetil, prednisolone, and basiliximab based on the institutional immunosuppression schedule. [ 16 ]…”
Section: Methodsmentioning
confidence: 99%
“…43 Therefore, UCSF criteria may be a more achievable downstaging endpoint before LDLT. Although some case series have reported successful downstaging of HCC with portal vein tumor thrombus often using Y-90 radio-embolization, [78][79][80][81] the small number of patients and limited follow up make it difficult to propose guidelines for LDLT in this population at present.…”
Section: Role Of Tumor Downstaging In Ldltmentioning
confidence: 99%